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2ABSTRACT: Up to twenty percent of solid tumors are characterized by DNA mismatch 
repair (MMR) deficiency and microsatellite instability (MSI) that confer resistance to 
standard of care chemotherapy. MMR-deficient cancers have an increased mutation rate 
and accumulate DNA mismatches. We previously described a class of compounds, 
rhodium metalloinsertors, that bind DNA mismatches with high specificity and 
selectivity and have potential as targeted therapy. [Rh(chrysi)(phen)(PPO)]2+ (RhPPO) is 
the most potent, selective compound in this class and acts by targeting DNA 
mismatches, resulting in preferential cytotoxicity to MMR-deficient cancers. To explore 
further the cellular mechanism of action of RhPPO, we conjugated the metal complex to 
a fluorescent probe, cyanine 3 (Cy3). RhPPO-Cy3 binds DNA mismatches and retains 
the selectivity and potent cytotoxic activity of RhPPO for MMR-deficient cell lines. 
RhPPO-Cy3 forms discrete foci in the cell nucleus that overlap with sites of DNA 
damage, suggesting that the lesions occur at or near DNA mismatch sites. RhPPO-Cy3 
foci persist over time, despite initial processing of the lesion and recruitment of repair 
proteins, consistent with the idea that the complex binding to a mismatch prevents 
repair. RhPPO-Cy3 binding does not lead to activation of p53 and the apoptotic 
pathway. Together, these findings support the idea that RhPPO-Cy3 binding leads to 
irreversible DNA damage at DNA mismatches that enables selective cytotoxicity to 
MMR-deficient cells.
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3INTRODUCTION     
 DNA mismatch repair (MMR) is a key mechanism that detects and repairs 
mismatched DNA base pairs that arise during DNA replication or from exposure to 
DNA damaging agents.1,2,3 Cells with impaired MMR ability accumulate mutations and 
develop genome instability that can cause or contribute to cancer. MMR is a complex 
molecular system where the MLH1/PMS2 and MSH2/MSH6 heterodimers recognize 
and bind DNA mismatches and recruit repair enzymes to excise and replace 
mismatched bases. Inactivation of any of the MMR genes by somatic or germline 
mutation or by epigenetic silencing results in a deficient MMR pathway.3,4,5 Deficiencies 
in the MMR machinery are associated with an increased mutation rate (100- to 1000-
fold) and occur in 15% of colorectal cancer (CRC) and up to 20% of many solid tumors.6-
10 It is well established that CRC patients with MMR-deficient tumors do not respond to 
standard care chemotherapy such as 5-fluorouracil, cisplatin, temozolomide, or 
pyrimidine analogues.11,12  In the last few years, MMR-deficient CRC, as well as other 
MMR-deficient cancers, have shown remarkable response to immunotherapy with anti-
programmed death-1 (PD-1) antibodies.13,14 However, many patients relapse over time, 
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4and durability of response is likely to require combination therapy.15, 16 Therefore, new 
therapies are still needed for effective treatment of MMR-deficient cancers.
The high mutation rate of MMR-deficient cancers leads to heterogeneity that is 
challenging to target therapeutically. We have proposed targeting the state of MMR 
deficiency, and specifically DNA mismatches, as a strategy for selective killing of MMR-
deficient cancer cells.17,18 Rhodium metalloinsertors are a class of compounds that bind 
DNA mismatches with high specificity and selectivity18, 19, 20 Thermodynamic 
destabilization at a mismatch site allows the compounds to insert via the aromatic 
chrysi (5,6-chrysenequinone diimmine) ligand into the DNA through the minor groove. 
This binding mode is non-covalent but ejects the mismatched base pairs outside of the 
DNA helix, generating DNA lesions that activates the DNA damage response and 
drives selective killing of MMR-deficient cells.18,20
2+
[Rh(chrysi)(phen)(PPO)]2+
2Cl
Rh
N
H
H
N
N
N
O
N
Rh
N
H
H
N
N
N
N
N
[Rh(chrysi)(bpy)2]3+
3+
(RhPPO)
2nd generation1st generation
3Cl
RhPPO-Cy3
Rh
N
H
H
N
3+
3Cl
O
N
N
N
N
N
O
O
H
N
O
N
A B
C
Page 4 of 39
ACS Paragon Plus Environment
Biochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
5Chart 1. Chemical structures of compounds used in this study. (A) RhPPO, a second 
generation metalloinsertor, (B) [Rh(chrysi)(bpy)2]Cl3, representing the first generation of 
metalloinsertors, (C) RhPPO-Cy3 conjugate which, in the presence of mismatched DNA, 
emits light through its cyanine3 fluorophore; the PPO ligand is shown in blue, and Cy3 
fluorophore is shown in red.
We have described a second generation of rhodium metalloinsertors where one 
of the bidentate ligands is metalated via a rhodium-oxygen bond, which differs from the 
first generation of rhodium metalloinsertors that employ N^N coordination (Chart 
1).21,22 This new ligand coordination reduces the total charge of the metal complex from 
+3 to +2 and has a direct consequence on the pKa of immine protons on the chrysi 
ligand and therefore bulk of the chrysi ligand. The lead compound in this series, 
[Rh(phen)(chrysi)(PPO)]2+ (RhPPO) demonstrates remarkably high cellular potency and 
selectivity towards MMR-deficient cells relative to the first generation of 
compounds.22,23 These findings were extended to a panel of 27 CRC cell lines, where 
RhPPO demonstrated preferential cytotoxic activity in the MMR-deficient cell lines 
relative to the MMR-proficient cell lines.24 Specifically, RhPPO cytotoxic activity 
showed a strong correlation with the level of DNA mismatches present in the cells, as 
detected with a fluorescent rhodium conjugate, RhCy3.24,25 These findings strongly 
suggested that the cellular target of RhPPO is a DNA mismatch. 
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6The mechanism that drives the high cellular potency of RhPPO is not well 
understood. RhPPO causes DNA lesions that lead to cell death primarily by necrosis, 
which is distinct from the mechanism of cisplatin and other DNA-damaging drugs that 
induce cell death primarily through apoptosis.26,27 Our first-generation rhodium 
conjugate, RhCy3, emits a fluorescent signal in cells with DNA mismatches and 
functions primarily as a diagnostic probe.25 In the present study, we characterize a 
fluorescent conjugate of RhPPO, RhPPO-Cy3, which not only acts as a probe that binds 
DNA mismatches but also functions to promote cytotoxicity of MMR-deficient cells. 
RhPPO-Cy3 binding to DNA mismatches is visualized as discrete foci in the nucleus of 
live cells, enabling mechanism of action studies that further explore the nature of the 
DNA lesions caused by PPO-based metalloinsertor compounds. We find that RhPPO-
Cy3 binding causes DNA breaks and activates the DNA damage response. The RhPPO-
Cy3 foci overlap with DNA damage foci that contain phosphorylated histone H2AX 
(phospho-H2AX) and Rad51, suggesting that the DNA breaks occur at the DNA 
mismatch site and undergo initial resection. However, although cell cycle progression 
appears blocked after RhPPO-Cy3 binding, cells do not activate the p53/p21 axis that 
would trigger cyclin-dependent kinase (CDK)-dependent cell cycle arrest and initiation 
of apoptosis. Instead, the Rh-PPO foci persist, indicating rhodium-bound DNA 
mismatches are not repaired, and the cells undergo cell death by necrosis. Together 
these findings suggest that the DNA lesions induced by RhPPO-Cy3 binding occur at 
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7the mismatched base pair and that the cellular context of this DNA damage prevents its 
recognition by the DNA repair or apoptotic machinery.
MATERIALS AND METHODS
Materials. All reactions except when mentioned were performed under a dry 
atmosphere of argon. [Rh(NH3)5Cl]Cl2 was purchased from Strem Chemical, Inc. 
(Newburyport, MA), 2,2’-dipyridylamine (HDPA), 1,2-bis(2-iodoethoxy)ethane, 
anhydrous iPr2NH, anhydrous DMF, (2-(1H-benzotriazol-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HBTU) and Sephadex ion exchange resin 
were obtained from Sigma-Aldrich and used as purchased. Sep-Pak C18 solid phase 
extraction cartridges were purchased from Waters Chemical Co. (Milford, MA). Flash 
chromatographic purifications were performed using 40-63 µm silica gel or Sep-Pak 
C18 cartridges. HPLC purifications were performed on an HP1100 high-pressure liquid 
chromatography system equipped with a diode array detector using a Varian DynaMax 
C18 semi-preparative column. Mass spectrometry was performed at the California 
Institute of Technology mass spectrometry facility. UV-vis absorption spectra were 
recorded on a Cary 100 Bio spectrophotometer.  1H, 13C NMR spectra were recorded on 
a Bruker Spectrometers (400 or 300 MHz). 1H, 13C chemical shifts were reported to the 
delta scale in ppm relative to the residual peak of the deuterated used solvent as 
internal standards: chloroform-d1 (1H: δ = 7.26 ppm; 13C: δ = 77.16 ppm), methanol-d4 
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8(1H: δ = 3.31 ppm; 13C: δ = 49.00 ppm), acetonitrile-d3 (1H: δ = 1.94 ppm; 13C: δ = 118.26 
ppm). 
Synthesis and characterization of RhPPO-Cy3 conjugate. The 2-(pyridine-2-
yl)propan-2-ol (PPO) ligand and DPA-Cy3 were prepared according to previously 
reported procedures.21,25 [Rh(chrysi)(NH3)4]Cl3 was obtained from reacting 
[Rh(NH3)6](OTf)3 and 5,6-chrysenquinone according to published procedures.28
Synthesis of RhDPA-Cy3. A Schlenk flask was charged with 
[Rh(chrysi)(NH3)4]Cl3 (0.091 mmol, 80 mg) and DPA-Cy3 (0.111 mmol, 90 mg) and the 
solids were dissolved with a water/acetonitrile/ethanol (2/3/3 ml) mixture. The solution 
was degassed with argon for about 30 - 40 minutes and the Schlenk flask was refluxed 
at 95C for 20 hours. Afterwards, the solution was cooled to ambient temperature and 
loaded on a QAE Sephadex anion exchange column equilibrated with 0.1 M MgCl2 
aqueous solution. The collected solution was concentrated under vacuum and purified 
using a Waters Sep-Pak C18 SiO2 column. The column was first eluted with H2O/ACN 
(10%) allowing the elimination of unreacted starting materials while the desired 
product sticks to the top which is then eluted with H2O (0.1 % TFA)/ ACN 25%. The 
collected pure fractions were lyophilized yielding the product as dark red solids (68 mg, 
61%). NMR 1H (400 MHz, Acetonitrile-d3) δ 9.12 (d, J = 5.1 Hz, 1H), 9.05 (d, J = 5.8 Hz, 
1H), 8.80 (d, J = 8.5 Hz, 1H), 8.57 (d, J = 6.5 Hz, 1H), 8.26 (t, J = 13.5 Hz, 1H), 8.10 – 7.98 
(m, 2H), 7.92 (d, J = 8.8 Hz, 1H), 7.85 – 7.79 (m, 2H), 7.77 (d, J = 8.9 Hz, 1H), 7.70 – 7.64 
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9(m, 1H), 7.57 – 7.41 (m, 7H), 7.38 (dd, J = 7.8, 1.2 Hz, 1H), 7.36 – 7.31 (m, 1H), 7.29 (dd, J = 
7.4, 1.4 Hz, 1H), 7.22 – 7.13 (m, 2H), 7.09 (d, J = 1.7 Hz, 1H), 6.83 – 6.76 (m, 2H), 6.51 (d, J 
= 8.3 Hz, 1H), 6.21 (d, J = 13.7 Hz, 1H), 6.11 (d, J = 13.3 Hz, 1H), 4.20 (p, J = 3.8 Hz, 2H), 
4.08 (s, 4H), 3.77 (s, 3H), 3.55 (d, J = 25.5 Hz, 2H), 3.45 (s, 3H), 3.33 (s, 3H), 3.24 (d, J = 6.4 
Hz, 1H), 3.10 (s, 2H), 2.97 (dt, J = 9.8, 4.9 Hz, 2H), 1.55 (s, 6H), 1.45 (s, 3H), 1.41 (s, 3H). 
13C NMR (101 MHz, Acetonitrile-d3) δ 176.8, 175.3, 174.6, 167.5, 160.7, 160.4, 155.2, 155.0, 
153.8, 153.5, 151.2, 145.7, 143.4, 143.2, 143.1, 141.7, 140.7, 137.2, 136.3, 136.2, 134.5, 134.2, 
131.2, 131.1, 130.7, 130.5, 129.9, 129.4, 129.4, 129.0, 128.5, 126.5, 126.2, 126.2, 123.2, 122.9, 
122.9, 122.5, 121.5, 120.8, 119.0, 118.4, 115.7, 112.2, 110.6, 104.2, 102.9, 71.0, 70.4, 70.2, 67.0, 
51.9, 50.2, 49.2, 39.8, 32.1, 27.7, 27.4. TOF-MS ESI calculated m/z = 1225.3816 for [M - 2H 
+ OTf]+, found 1225.3796; calculated m/z = 538.2148 for [M - H]2+, found 538.2071. 
 Synthesis of RhPPO-Cy3. A Schlenk flask was charged with water (2 mL) and 
degassed with argon for about 40 minutes. RhDPA-Cy3 (34 mg, 0.027 mmol) was 
loaded into the solution and 2 mL of ethanol were additionally added. After degassing 
the solution for 5 more minutes, PPO ligand (6.0 mg, 0.044 mmol) was finally added 
and the reaction mixture was allowed to stir at 95C overnight. After cooling to ambient 
temperature, the crude was concentrated under vacuum and loaded on a Sep-Pak C18 
SiO2 column for purification. Additional purifications were performed using HPLC, 
thus yielding the product as dark-red solids (6 mg, 17%). NMR 1H (400 MHz, 
Acetonitrile-d3) δ 8.53 – 8.42 (m, 2H), 8.31 – 8.29 (m, 3H), 8.15 – 8.07 (m, 1H), 7.95 (d, J = 
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10
1.7 Hz, 1H), 7.88 (dd, J = 8.3, 1.7 Hz, 1H), 7.65 (ddd, J = 8.5, 7.2, 2.0 Hz, 2H), 7.60 – 7.54 
(m, 3H), 7.54 – 7.44 (m, 3H), 7.43 – 7.33 (m, 5H), 7.33 – 7.28 (m, 1H), 7.25 (d, J = 8.3 Hz, 
1H), 7.19 (d, J = 8.4 Hz, 1H), 6.97 (ddd, J = 7.3, 5.0, 0.9 Hz, 2H), 6.43 (d, J = 13.8 Hz, 1H), 
6.38 (d, J = 13.6 Hz, 2H), 6.30 (dd, J = 13.3, 3.5 Hz, 2H), 4.31 (t, J = 6.2 Hz, 2H), 3.74 (t, J = 
6.2 Hz, 2H), 3.66 (s, 2H), 3.65 – 3.61 (m, 6H), 3.59 (d, J = 2.8 Hz, 2H), 3.56 – 3.49 (m, 4H), 
1.76 (s, 3H), 1.75 (s, 3H), 1.74 (s, 6H), 1.74 (s, 6H). TOF-MS ESI calculated m/z = 
1177.4449 for [M - 2H]+, found 1177.3186; calculated m/z = 589.7300 for [M - H]2+,  found 
589.7303. UV-vis (in Tris 5 mM, 200 mM NaCl, pH 7.4): (552nm)  = 61,000 M-1 cm-1; 
(267nm)  = 28,000 M-1cm-1.
Photophysical measurements. Luminescence spectra were recorded using a QE 
Pro High Performance Spectrometer with a back-thinned, TE-cooled CCD detector 
controlled by the OceanView data acquisition and analysis software package (Ocean 
Optics, Inc.). Sample excitation was provided by a 455 nm LED (Thorlabs model 
M455L2). The emission spectra were recorded in Tris buffer solution (5 mM Tris, 200 
mM NaCl, pH 7.4) at 25°C using a water circulation system. Excitation wavelength was 
λEx = 455 nm and the emission integral was reported after each addition of DNA, as a 
scalar function from 548 to 675 nm. The flourescence titrations were performed twice for 
the mismatched (MM) DNA and once for the well-matched (WM) DNA. The dsDNA 
was a 27-mer sequence, 5’-GAC CAG CTT ATC ACC CCT AGA TAA GCG-3’ where the 
complementary MM strand comprises a (C) at the mismatched site versus (G) for WM. 
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11
The RhPPO-Cy3 fluorescence titrations with increasing amounts of MM dsDNA were 
used to determine the binding affinity of the conjugate with the mismatched DNA 
duplex. [DNA] was considered as concentration of mismatches on the full-length 
fragments, i.e. the 27-mer oligonucleotide. The plotted data were fit to a one-site specific 
binding equation curve with GraphPad Prism 7. 
Cell culture. HCT-116 N and HCT-116 O cells29 were grown in Roswell Park 
Memorial Institute (RPMI) 1640 medium supplemented with 10% fetal bovine serum 
(FBS), 2 mM L-glutamine, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, 
100 g/mL penicillin, 100 g/mL streptomycin, and 400 g/mL geneticin (G418). MMR-
deficient cell lines Lovo, DLD-1, SW48, RKO and KM12, and MMR-proficient cell lines 
LS1034, Colo320, SW948, SW1463 and SW837 were obtained from the American Type 
Culture Collection (ATCC) and grown in RPMI media with 10% FBS and 1% 
penicillin/streptomycin. Cells were maintained in tissue culture flasks (Corning Costar) 
at 37°C under 5% CO2
 
in a humidified atmosphere. 
Cell viability. Cells were plated in 96-well plates at 5000 cells/well in a volume 
of 90 µl.  Cells were incubated for 6 hours at 37°C, 5% CO2 prior to adding compound. 
The cells were then treated with RhPPO-Cy3 or cisplatin in a dose range, using a 1:2 
dilution series of 12 points, and incubated for 48 hours at 37°C.  The assay plate was 
equilibrated to room temperature for 15 minutes, and then cytotoxicity was assayed 
using a CellTiter-Glo assay (Promega), performed according to the manufacturer’s 
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12
instructions. The luciferase signal was recorded on a Biotek Neo2 plate reader or a 
FlexStation 3 Multi-Mode plate reader.  Percent viability was determined by the ratio of 
the luminescence of treated cells compared to untreated cells. EC50 values were 
determined by fitting the cell viability data points to a dose-response curve in 
GraphPad Prism 7. Experiments were performed in duplicate in at least three 
independent experiments.
Live cell images and colocalization studies. HCT-116 O cells were plated at 7000 
cells/well in 96-well plates (Greiner). Cells were incubated for 5 hours prior to adding 
compound at the concentrations indicated. The cells with compound were then 
incubated for 48 hours before analysis. For live cell imaging, 1 µM Hoechst dye 
(Thermo Fisher) was added to cells and incubated at 37°C for 90 minutes.  Cells were 
imaged on an Opera Phenix (Perkin Elmer) using 63x magnification. Cells were also 
fixed and permeabilized to enable colocalization studies. Cells were fixed in 4% 
paraformaldehyde and 0.5% Triton-X for 15 minutes. Then, the supernatant was 
aspirated off. Cells were blocked with biotin, according to manufacturer’s protocol 
(Thermo Fisher), and then incubated with 1X blocking buffer (Thermo Fisher) for an 
additional 30 minutes. Cells were incubated with primary antibodies for 60 minutes at 
ambient temperature, protected from light. Primary antibodies used were: anti-
phospho-H2AX (Millipore), anti-Rad51 (Cell Signaling), and anti-Cy3-biotin (Sigma). 
The anti-Cy3-biotin antibody was used to amplify the Cy3 signal on the RhPPO-Cy3 
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13
molecule, which otherwise underwent photobleaching during additional antibody 
staining. After incubation with primary antibodies, cells were washed three times with 
phosphate-buffered saline (PBS).  Secondary antibodies against phospho-H2AX (1:100, 
Millipore) and Streptavidin AF647 (1:1000, Thermo Fisher) were incubated with cells for 
45 minutes at room temperature.  Hoechst dye (1 g/ml; Sigma) was used to visualize 
the cell nuclei. Cells were then washed three times in PBS and then maintained in PBS 
with the plates sealed.  Cells were imaged using an Opera Phenix (Perkin Elmer) using 
63x magnification.
Image analysis was carried out using Acapella (Perkin Elmer) following image 
acquisition. Hoechst staining was used to define the cell nucleus, and then RhPPO-Cy3 
foci within the nucleus were identified based on intensity of the AF647 signal. Overlap 
of this signal with the AF488 channel was used to evaluate colocalization with pH2AX 
or Rad51
Comet assay. DNA damage was evaluated using a neutral Comet assay (Cell 
Biolabs), performed according to the manufacturer’s instructions. Cells were treated 
with compound as indicated, and then collected using a cell scraper, mixed with melted 
agarose, and pipetted onto slides. The samples were denatured and then analyzed by 
Tris-borate-EDTA (TBE) gel electrophoresis at 35 V for 60 minutes to separate DNA 
fragments from intact DNA. The samples were then stained with Vista Green 
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fluorescent dye to visualize the cellular DNA and imaged using an EVOS cell imaging 
system (Thermo Fisher).
Western blots. HCT-116 N and HCT-116 O cells were treated with compound as 
indicated for 24 hours at 37°C.  Cell pellets were then collected by non-enzymatic cell 
dissociation buffer (Thermo Fisher) and protein lysates were prepared in RIPA buffer 
(Pierce) containing a protease and phosphatase inhibitor cocktail (Thermo Fisher). Total 
lysate (40 µg) in running dye (Thermo Fisher) was incubated at 95°C for 5 minutes.  
Samples were then loaded onto a 4-12% NuPAGE SDS Gel (Thermo Fisher) and 
analyzed by electrophoresis for 60 minutes at 120 V. 
The iBlot2 Dry Blotting System (Thermo Fisher) was used to transfer proteins 
from the NuPAGE SDS Gel to a nitrocellulose membrane.  Proteins were transferred 
using the following protocol: 1 minute at 20 V, 4 minutes at 23 V, 2 minutes at 25 V.  
After transfer, the membrane was pre-wet in 1X Tris-buffered saline (TBS) for 2 minutes 
and then blocked with TBS Blocking Buffer (Odyssey) for 1 hour at ambient 
temperature with gentle shaking. The membrane was incubated with primary 
antibodies, phospho-p53 (serine 15) and p21 Waf1/Cip1 (Cell Signaling Technology) at 
1:1000 in blocking buffer + 0.2% Tween 20, overnight at 4°C with gentle shaking. The 
membrane was then washed 3X with 1X-TBS + 0.1%Tween 20 (TBS-T) at ambient 
temperature for 5 minutes. The membrane was incubated with appropriate secondary 
antibody coupled to IRDye-700 or IRDye-800 (LiCOR) at 1:10,000 in blocking buffer + 
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0.2% Tween 20, at ambient temperature for 1 hour with gentle shaking.  The membrane 
was then washed 3 times with 1X TBS-T and imaged with an Odyssey CLx (LiCOR).
RESULTS
Synthesis and characterization of a RhPPO-Cy3 conjugate. To further 
investigate the cellular mechanism of action of RhPPO, we synthesized a fluorescent 
analogue, the cyanine conjugate RhPPO-Cy3. RhPPO-Cy3 was designed to enable 
visualization of the molecule binding to DNA and interactions on chromatin, with 
similar potency and cell selectivity as the unconjugated molecule, RhPPO.  As 
illustrated in Scheme 1, the fluorophore is appended on the dipyridyl ligand through a 
polyethylene glycol (PEG) linker, leaving the PPO ligand intact. The synthesis 
procedure for DPA-Cy3 was previously described and reported in literature.25 RhPPO-
Cy3 was prepared following the synthesis approach indicated in Scheme 1, inspired by 
the previously reported RhCy3 conjugate.25 Briefly, DPA-Cy3 was refluxed with 
[Rh(Chrysi)NH3)4]3+ under anaerobic conditions giving RhDPA-Cy3 in good yields. 
Finally, PPO substitution of the ammonia ligands via an N^O coordination yielded the 
corresponding RhPPO-Cy3 complex. Since ammonia is a strong ligand, the rhodium 
ammine complexes are relatively stable, therefore explaining in part the low yield of the 
final reaction. Additionally, side reactions occur given the reactivity of rhodium 
complexes and the reaction conditions. During our preliminary results we noticed that 
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complexation of PPO with [Rh(chrysi)(NH3)4]3+ yielded preferentially the bis-
coordinated species instead of the mono-coordinated rhodium-PPO complex (data not 
shown). Given these observations and others not reported here, we proceeded first with 
DPA-Cy3 complexation, followed by PPO ligand coordination. 
RhPPO-Cy3
Rh
N
H
H
N
RhDPA-Cy3
N
NN
O O
H
N
O
N
N
Rh
N
H
H
N
NH3
NH3
NH3
NH3
HO N
PPO
DPA-Cy3 [Rh(chrysi)(NH3)4]Cl3
i)
ii)
I
O
N
N
N
N
N
O
O
H
N
NH3
NH3
Rh
N
H
H
N
3+
3Cl
O
N
N
N
N
N
O
O
H
N
O
N
4+
4Cl
3+
3Cl
Scheme 1. Synthesis pathway for RhPPO-Cy3 conjugate. i) ii) EtOH/ACN/H2O, 95C, 
overnight under anaerobic conditions followed by anion exchange using 0.1 M MgCl2. 
The synthesis of DPA-Cy3 and [Rh(chrysi)(NH3)4] has been previously reported.25, 28
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After HPLC purification, the compound was characterized using standard NMR 
techniques and high-resolution mass spectrometry; all the spectra are included in the 
Supplemental Information (Figures S1-S7). The RhPPO-Cy3 conjugate is soluble in 
aqueous solution. Its absorption spectrum corresponds to the sum of the absorption of 
the parent metal complex and Cy3 (Supplemental Information, Figure S8). Additionally, 
the presence of a large band at 430 nm marks charge transfer from the rhodium center 
to the chrysi ligand and reflects the protonated state of immines on the chrysi ligand.22 
After photoexcitation at 455 nm, RhPPO-Cy3 yields a weak luminescence centered at 
567 nm. The luminescence is increased and the maximum emission is slightly red 
shifted by 5 nm when RhPPO-Cy3 is incubated with a 27-mer double-stranded DNA 
(dsDNA) containing a single CC mismatch (Figure S8, Supplemental Information). This 
enhancement confirms that RhPPO-Cy3 binds mismatched dsDNA. 
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Figure 1. Fluorescence titrations with increasing amounts of WM DNA (blue) or MM 
DNA (red). [RhPPO-Cy3] = 2 µM, in Tris buffer (5mM Tris, 200 mM NaCl, pH = 7.4) at 
25°C. Ex = 455 nm, emission recorded from 548-675 nm. I0 is the integrated emission of 
RhPPO-Cy3 solution without DNA and, I represents the emission integral from 548-675 
nm as a scalar function measured after each addition of DNA. The 27-mer DNA 
sequence: 5’-GAC CAG CTT ATC ACC CCT AGA TAA GCG-3’ where the MM strand 
comprises a (C) at the mismatched site vs. (G) for WM. The titration points were fit to a 
one site – total binding equation using GraphPad Prism 7. Error bars represent the ratio 
of the standard deviation to the mean of duplicates.
RhPPO-Cy3 binds mismatched DNA with high affinity and specificity. For 
mechanistic studies, it was important that RhPPO-Cy3 have similar binding affinity to 
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that of the parent RhPPO molecule, although the RhPPO-Cy3 conjugate contains a PEG 
linker and an indocyanine fluorophore. Therefore, we examined the DNA binding 
affinity, KB, of RhPPO-Cy3 to duplex DNA with and without a single base mismatch 
through fluorescence titrations. The binding affinity defines the interaction strength 
between the duplex DNA and the fluorescent probe and is experimentally measured 
through the dissociation constant Kd =1/ KB.29 Thus, a 2 M Tris buffer solution of the 
fluorescent probe was titrated with increasing amounts of 27-mer dsDNA containing a 
central CC base-paired mismatch. While an increase in emission intensity is seen in the 
presence of mismatched (MM) dsDNA, negligible fluorescence intensity was observed 
with well matched (WM) dsDNA (Figure 1). This change in fluorescence intensity can 
be used to determine the dissociation constant by plotting the ratio of the fluorescence 
intensity versus the concentration of the duplex DNA. The data are then analyzed via a 
nonlinear fitting, using a one site binding – total equation, yielding a Kd of 0.55 ± 0.1 µM 
for the duplex containing a CC mismatch. Given the Kd value, the resulting binding 
affinity of RhPPO-Cy3 to the mismatched DNA sequence is KB(CC) = 1.8 x 106 M-1, 
which is comparable to that of other RhO metalloinsertors lacking the fluorescent tag, 
where the KB(CC) ranges from 1.5 – 9.2 x 106 M-1.21,22 In the current proof-of-concept 
study, we used only a duplex DNA containing a CC mismatch to evaluate the binding 
affinity of RhPPO-Cy3 versus that of the parent RhPPO complex. However, binding 
affinities of RhO metalloinsertors at all possible DNA mismatches have been 
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determined and reported to correlate directly with thermodynamic destabilization of 
the mismatch site.22 Additionally, fluorescence titrations were performed also in the 
presence of increasing amounts of well-matched dsDNA, but little variation in 
fluorescence intensity was observed. Overall, these results indicate that appending the 
cyanine fluorophore through a small PEG linker on the dipyridyl ligand does not have a 
significant impact on the specific DNA binding affinity of RhPPO-Cy3.
RhPPO-Cy3 is cytotoxic to MMR-deficient cells. The activity of RhPPO-Cy3 was 
evaluated in isogenic HCT-116 cell lines HCT-116 O, which is MMR-deficient due to 
homozygous mutation lacking MLH1, and HCT-116 N which is MMR-proficient due to the 
presence of an additional copy of Chromosome III that expresses wild type MLH1.30,31 RhPPO-
Cy3 preferentially decreased cell viability of HCT-116 O cells, with a half-maximal effective 
concentration (EC50) of 1.0 ± 0.1 µM (Figure 2).  In contrast, the same concentration showed less 
cell killing (<10%) against the MMR-proficient HCT-116 N cells, where the EC50 was 1.9 ± 0.2 
M.  RhPPO-Cy3 activity increased over time, with maximal activity by 72 hours (Figure 3; 
Supplemental Information, Figure S9). The preferential cytotoxicity of RhPPO-Cy3 for MMR-
deficient cells was also observed against other CRC cell lines (Supplemental Information, Figure 
S10).24 Overall, RhPPO-Cy3, like the unconjugated parental compound RhPPO, shows potency 
and selectivity for MMR-deficient cells, indicating that it is a suitable candidate for studies of 
compound localization and cellular mechanism of action.
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Figure 2. RhPPO-Cy3 is preferentially cytotoxic to MMR-deficient HCT-116 O cells. 
HCT-116 O and HCT-116 N cells were treated with RhPPO-Cy3 in a 12-point dose 
response. After 72 hours incubation, cell viability was assessed with a Cell Titer-glo 
assay. The graph shows data for duplicate samples from a representative assay. 
RhPPO-Cy3 forms foci in the cell nucleus that overlap with DNA damage foci. 
The cellular localization of RhPPO-Cy3 was evaluated by live cell imaging in HCT-116 
O and HCT-116 N cells. Cells were treated with 5 µM RhPPO-Cy3, a concentration 
higher than the cell EC90, for 24 hours and then visualized for Cy3 fluorescence. Cellular 
uptake of the compound was observed, with RhPPO-Cy3 foci evident both in the cell 
nucleus and around the periphery of the nuclear membrane (Figure 3A). Nuclear 
RhPPO-Cy3 foci were observed in the MMR-deficient HCT-116 O cells, consistent with 
the idea that the complex binds to genomic DNA mismatches.
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Figure 3. RhPPO-Cy3 forms nuclear foci that overlap with DNA damage foci. HCT-116 
O and HCT-116 N cells were treated with RhPPO-Cy3, and RhPPO-Cy3 localization 
was evaluated in live cells (A), or with DNA damage markers phospho-H2AX (B) or 
Rad51 (C) in fixed, permeabilized cells. Cells were counterstained with Hoechst dye to 
detect the cell nuclei. Scale bar, 20 m. In Figure 3B and 3C (third image) RhPPO-Cy3 is 
abbreviated as PPO-Cy3.
The selective cytotoxicity of the parent compound, RhPPO, is associated with the 
formation of nuclear foci that contain phospho-H2AX, a marker for DNA double-strand 
breaks (DSBs).23 The fluorescence of RhPPO-Cy3 conjugate enabled us to assess whether 
the DNA damage foci marked by phospho-H2AX occurred at sites of rhodium 
metalloinsertor binding. We initially treated cells with 5 µM RhPPO-Cy3 for 24 hours, 
imaged the fluorescent cyanine signal, and then fixed and permeabilized the cells to 
stain for phospho-H2AX and re-imaged the same cells. To obtain a more optimal signal, 
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fixed permeabilized cells were stained with an anti-Cy3 antibody to detect RhPPO-Cy3. 
In co-staining experiments with phospho-H2AX, the nuclear RhPPO-Cy3 foci exhibited 
partial overlap with phospho-H2AX foci (20 + 4%) (Figure 3B), suggesting that the DNA 
lesions formed by RhPPO-Cy3 binding occur at or near sites of DNA mismatches. 
Phospho-H2AX, as a component of chromatin, spans megabases of DNA 
surrounding a DNA break.32 To explore further the potential colocalization of RhPPO-
Cy3 with DNA damage foci, we compared RhPPO-Cy3 nuclear localization to that of 
Rad51, a strand exchange enzyme that binds single-stranded DNA (ssDNA) formed 
from resection of DNA DSBs.33 RhPPO-Cy3 foci showed strong overlap with Rad51 foci 
(24 + 6%)(Figure 3C). Neutral comet assays confirmed that RhPPO-Cy3 treatment 
induced DNA DSBs (Supplemental Information, Figure S11).  After 24 hours treatment 
with 5 µM RhPPO-Cy3, HCT-116 O and HCT-116 N cells analyzed by TBE 
electrophoresis exhibited Comet tails indicating the presence of DNA damage; 29.1 + 6.7 
% of the MMR-deficient HCT-116 O cells displayed Comet tails, compared to 18.9 + 3.9 
% of HCT-116 N cells. These findings further support the idea that RhPPO-Cy3 binding 
to cellular DNA mismatches generates DNA damage at or near the mismatch site. 
The DNA lesions induced by RhPPO-Cy3 could be a direct consequence of the 
complex binding to a mismatch (e.g. by causing extrusion of the mismatched base pair 
and activation of a DNA-binding protein, generating damage) or could result indirectly 
as cells attempt to unwind the DNA helix for replication or transcription. To test these 
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possibilities, HCT-116 O and HCT-116 N cells were treated with the CDK4/6 inhibitor 
palbociclib for 24 hours to induce G1/S phase arrest, and then cell killing by RhPPO-Cy3 
was compared in cells maintained in cell cycle block versus cells where the inhibitor 
was washed out to allow cell cycle progression. RhPPO-Cy3 was cytotoxic to cells 
treated with palbociclib, and the cell killing was further increased when cells re-entered 
the cell cycle and palbociclib was washed out (Figure 4A). The cytotoxicity observed 
was due to RhPPO-Cy3 treatment, as little to no cell killing occurred in the absence of 
the compound. Cytotoxicity mediated by cisplatin was increased in cycling cells, 
consistent with its known mechanism of action. These studies suggest that RhPPO-Cy3 
induces DNA damage directly upon binding to cellular DNA mismatches. 
Figure 4. RhPPO-Cy3 does not activate p53/ p21 to initiate apoptosis. HCT-116 O and 
HCT-116 N cells were treated with 5 µM RhPPO-Cy3 and analyzed for mechanism of 
cell death. (A) RhPPO-Cy3 induces cell death in cells arrested in G1/ S phase as well as 
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in cycling cells. Cells were blocked in G1/S using 1 mM palbociclib, then RhPPO-Cy3 or 
cisplatin was added to cells held in arrest (black bars) or released back into the cell cycle 
(gray bars). Cell viability was assessed by CellTiter-Glo. Results from duplicate samples 
from a representative experiment are shown. (B) Cells that were untreated, or treated 
with 5 µM RhPPO-Cy3 or 36 µM cisplatin for 24 hours, were stained for Nuclear Green 
DCS dye as a marker for necrosis. Live cells were visualized with Hoechst dye. Scale 
bar, 20 m. (C) Protein lysates were prepared from HCT-116 O and HCT-116 N cells 
that were untreated, or treated with 5 mM RhPPO-Cy3, 36 µM cisplatin, or 25 µM 
oxaliplatin for 24 hours. 40 µg of protein was analyzed for phospho-p53 and total p21 
proteins. Blots were also probed for actin to confirm similar amounts of protein in each 
sample. 
RhPPO-Cy3 does not activate the p53-dependent apoptotic response.  In time 
course studies, we observed that the RhPPO-Cy3-induced nuclear damage foci 
persisted until cell death occurred. Imaging analysis of the mechanism of cell death 
showed that RhPPO-Cy3 treatment led to necrosis, unlike cisplatin which causes very 
little necrotic cell death (Figure 4B). Consistent with these findings, RhPPO-Cy3 
treatment did not lead to activation or accumulation of the p53 protein (Figure 4C). 
RhPPO-Cy3 also did not induce p21, a downstream target of p53 that mediates cell 
cycle arrest.  In contrast, HCT-116 O and HCT-116 N cells underwent apoptosis in 
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response to DNA damage induced by cisplatin treatment (Figure 4C), suggesting that 
the lesions caused by RhPPO-Cy3 binding do not trigger a cell cycle checkpoint or the 
apoptotic pathway. These results support the hypothesis that the DNA lesions induced 
by RhPPO-Cy3 binding to DNA mismatches are not able to be repaired in the presence 
of the compound and also prevent cross-talk between DNA checkpoint proteins and 
p53, the key mediator of the apoptotic pathway.
DISCUSSION
DNA mismatches present in MMR-deficient cancer cells present an opportunity 
for selective therapeutic targeting. The rhodium metalloinsertor RhPPO is characterized 
by high cellular potency across MMR-deficient cell lines,22, 24 and we have proposed that 
its buckled orientation in the DNA minor groove leads to a pronounced extrusion of the 
mismatched base pair from the DNA helix that activates DNA-binding proteins to 
generate DNA lesions.22, 23 Crystallography efforts are ongoing to address the molecular 
structure of RhPPO bound to the DNA mismatch. As an alternative approach, we 
generated a fluorescent conjugate of RhPPO to enable direct visualization of the 
compound binding and activity within cells. 
Our first-generation fluorescent probe, RhCy3, demonstrated fluorescence 
intensity that correlated with the presence of DNA mismatches and with RhPPO 
cytotoxicity24.  In the current study, we directly labeled RhPPO with a fluorescent 
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conjugate to generate RhPPO-Cy3. This probe exhibited similar binding affinity, cell 
activity and selectivity as RhPPO, indicating that the fluorescent conjugate has 
appropriate characteristics to enable studies of the cellular mechanism of action. 
RhPPO-Cy3 enabled the first direct visualization of rhodium metalloinsertor 
localization to discrete foci within the cell nucleus and overlapped with DNA damage 
foci containing phospho-H2AX and Rad51. These data support the idea that 
RhPPO/RhPPO-Cy3 binds DNA mismatches in nuclear DNA and generates DNA 
damage at or near the DNA mismatch site upon binding. RhPPO-Cy3 selective 
cytotoxicity is observed in cell lines with mutation or inactivation of MLH1, MSH2 or 
other MMR genes, consistent with the rhodium metalloinsertor targeting the state of 
MMR deficiency.
RhPPO-Cy3 activates the DNA damage checkpoint and recruits Rad51, 
suggesting that the lesions include DNA DSBs that undergo initial processing to form 
regions of single-stranded DNA. Although RhPPO-Cy3 binding is noncovalent, the foci 
persist over time, suggesting that the mismatch site remains unrepaired as long as the 
compound is present. The DNA lesion may involve the mismatched base pairs and 
could require MMR for repair. However, RhPPO-Cy3 foci persist both in HCT-116 O 
and HCT-116 N cells, suggesting that MMR is not a major mechanism for repair of the 
lesions. Instead, the lesions may activate the nucleotide excision repair (NER) pathway, 
which recognizes bulky lesions that distort the DNA helix, independent of sequence or 
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DNA structure.34 Repair by NER requires verification of the DNA damage.35 The lesions 
caused by RhPPO-Cy3 also might be in a chromosomal context that is not accessible to 
NER or other DNA repair enzymes. MMR-deficient cancer cells often have mutations in 
genes involved in DNA repair.36 Alternatively, the cell cycle block resulting from 
RhPPO-Cy3 binding may inhibit recruitment of appropriate repair factors to the DNA 
lesions. Interestingly, RhPPO-Cy3-induced DNA damage does not lead to upregulation 
of p53 or p21, which mediate checkpoint-dependent cell cycle arrest and apoptosis. We 
propose that RhPPO-Cy3 binding leads to necrosis as a default cell death pathway after 
the irreparable DNA lesions fail to induce cell death by apoptosis. A model for the 
RhPPO-Cy3 mechanism of action is shown in Figure 5. 
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DNA damage response activation
pH2AX
pH2AX
Rad51
Rh
Rh
Rh
RhPPO-Cy3 binding to DNA mismatchRh
p21, p53 
activation X
Apoptosis NecrosisDNA Repair
DSB breaks
Damage resection
X
Figure 5. Model for RhPPO-Cy3 mechanism of action of cytotoxicity. Mismatch binding 
generates DNA damage that activates pH2AX and Rad51, indicating DSBs form and undergo 
initial resection. Further repair of the lesion does not occur, potentially due to inaccessibility to 
the lesion or a physical block to cell cycle progression. Cells are unable to signal the damage to 
p53 to trigger apoptosis. Instead, the primary mode of cell death is necrosis. See text for 
additional details.
CONCLUSION
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Targeting of DNA mismatches with rhodium metalloinsertors such as RhPPO 
provides a therapeutic approach that is distinct from current strategies such as 
platinum-based chemotherapy or immune checkpoint blockade with anti-PD-1 
antibodies. RhPPO-Cy3, as a fluorescent analog, provides a means to probe the 
mechanism of action of these rhodium metalloinsertors in detail. The rhodium 
complexes yield DNA lesions that promote the recruitment of repair proteins but do not 
trigger the canonical damage-induced apoptosis pathway nor to the activation of p53. 
This response to DNA damage raises the possibility that cells may be less likely to 
develop resistance to metalloinsertors than occurs with standard chemotherapy.  
RhPPO and RhPPO-Cy3 thus enable the molecular detection of cellular mismatches and 
antitumor activity with high cell selectivity. This strategy therefore provides a 
differentiated therapeutic option for the treatment of MMR-deficient cancers. 
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